SGL Investment Advisors Inc. Purchases New Holdings in Insulet Co. (NASDAQ:PODD)

SGL Investment Advisors Inc. purchased a new position in Insulet Co. (NASDAQ:PODD) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 3,459 shares of the medical instruments supplier’s stock, valued at approximately $805,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Blue Trust Inc. raised its position in shares of Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 58 shares during the last quarter. International Assets Investment Management LLC bought a new position in shares of Insulet in the second quarter worth approximately $32,000. Venturi Wealth Management LLC increased its position in shares of Insulet by 633.3% during the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 133 shares in the last quarter. UMB Bank n.a. lifted its position in Insulet by 81.0% in the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after acquiring an additional 81 shares in the last quarter. Finally, 1620 Investment Advisors Inc. bought a new stake in shares of Insulet in the 2nd quarter worth $52,000.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on PODD. Sanford C. Bernstein started coverage on Insulet in a research report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 target price for the company. Piper Sandler increased their price objective on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. Morgan Stanley lifted their target price on shares of Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Citigroup boosted their price objective on Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a research report on Tuesday, October 1st. Finally, Raymond James lifted their target price on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research note on Monday, October 14th. Three investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, Insulet presently has an average rating of “Moderate Buy” and a consensus target price of $253.27.

Insulet Stock Performance

Shares of NASDAQ:PODD opened at $265.47 on Monday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The firm has a market cap of $18.62 billion, a PE ratio of 45.46, a price-to-earnings-growth ratio of 4.06 and a beta of 1.21. The firm’s 50 day simple moving average is $247.48 and its 200-day simple moving average is $217.32. Insulet Co. has a one year low of $160.19 and a one year high of $279.40.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.